Kolexia
Coppo Paul Hématologie
Coppo Paul
Hématologie
Hôpital Saint-Antoine
Paris, France
416 Activités
60 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Purpura thrombotique thrombocytopénique Purpura Purpura thrombopénique Microangiopathies thrombotiques Lymphomes Syndrome hémolytique et urémique Thrombose Purpura thrombopénique idiopathique Maladies rares

Collaborateurs

Voir plus
Veyradier Agnes
Veyradier Agnes
Hôpital Lariboisière, Paris, France
Galicier Lionel
Galicier Lionel
Hôpital Saint-Louis, Paris, France
Benhamou Ygal
Benhamou Ygal
Hôpital Charles Nicolle, Rouen, France
Azoulay Elie
Azoulay Elie
Hôpital Saint-Louis, Paris, France

Industries

Voir plus
Sanofi
82 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
40 collaboration(s)
Dernière en 2023
Janssen
15 collaboration(s)
Dernière en 2023
Sandoz
7 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Assessment of epidemiology and outcomes of adult patients with kidney-limited thrombotic microangiopathies.
Kidney international   29 février 2024
Plasmablastic lymphoma: better refine prognosis.
Blood   12 janvier 2024
[Congrès ASH 2023] Interview Paul COPPO 🎙
Youtube @ Filière de Santé Maladies Rares MaRIH   10 janvier 2024
Alemtuzumab-induced immune-mediated thrombotic thrombocytopenic purpura: A newly described drug-related autoimmune disease.
British journal of haematology   19 décembre 2023
Angioœdèmes par déficit acquis en C1-inhibiteur et lymphomes
87e CONGRÈS FRANÇAIS DE MÉDECINE INTERNE   01 décembre 2023
Management and follow-up of pregnancy-onset thrombotic thrombocytopenic purpura: the French experience.
Blood advances   01 décembre 2023
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura: A Phase 3b, Prospective, Open-label, Multicenter, Single Treatment Arm, Continuation Study of the Safety and Efficacy of TAK-755 (rADAMTS13, Also Known as BAX 930/SHP655) in the Prophylactic and On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP; Upshaw-Schulman Syndrome, or Hereditary Thrombotic Thrombocytopenic Purpura)
Essai Clinique (Takeda Pharmaceutical)   02 novembre 2023
Clinical Outcomes of Congenital Thrombotic Thrombocytopenic Purpura: A Multinational Chart Review Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)
65th ASH Annual Meeting Abstracts   02 novembre 2023
Pregnancy-Related Outcomes in Patients with Congenital Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of a Retrospective Chart Review Study
65th ASH Annual Meeting Abstracts   02 novembre 2023